Literature DB >> 18654006

Impact of culprit plaque composition on the no-reflow phenomenon in patients with acute coronary syndrome: an intravascular ultrasound radiofrequency analysis.

Yasutomi Higashikuni1, Kengo Tanabe, Shuzou Tanimoto, Jiro Aoki, Hirosada Yamamoto, Gaku Nakazawa, Ruri Chihara, Yoshinobu Onuma, Shuji Ohtsuki, Atsuhiko Yagishita, Sen Yachi, Hiroyoshi Nakajima, Kazuhiro Hara.   

Abstract

BACKGROUND: The difference in the culprit plaque composition of acute coronary syndrome (ACS) patients with and without the no-reflow phenomenon has not been fully evaluated. METHODS AND
RESULTS: Intravascular ultrasound radiofrequency data of culprit plaques were obtained and analyzed in 49 ACS patients. The no-reflow phenomenon was defined as a decrease of at least 1 grade in 'Thrombolysis In Myocardial Infarction' flow immediately after mechanical dilatation compared with before mechanical dilatation, with no evidence of thrombus, spasm, or dissection. The no-reflow phenomenon was observed in 9 individuals. Culprit plaques with the no-reflow phenomenon contained a higher percentage of necrotic core component and a smaller percentage of fibrous component than plaques in the patients without the no-reflow phenomenon (necrotic core component, 22.1+/-9.3% vs 11.7+/-7.9%, p=0.0011; fibrous component, 59.6+/-11.2% vs 68.3+/-10.2%, p=0.027). Multivariate analysis identified the percentage of necrotic core component as an independent predictor of the no-reflow phenomenon after adjustment for plaque geometry and procedural factors (odds ratio, 1.7; 95% confidence interval, 1.1 to 2.5; p=0.015).
CONCLUSION: Culprit plaques of patients with the no-reflow phenomenon differ from those in patients without the no-reflow phenomenon.

Entities:  

Mesh:

Year:  2008        PMID: 18654006     DOI: 10.1253/circj.72.1235

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

Review 1.  Applications of grayscale and radiofrequency intravascular ultrasound to image atherosclerotic plaque.

Authors:  Somjot S Brar; Gary S Mintz; Akiko Maehara; Gregg W Stone
Journal:  J Nucl Cardiol       Date:  2010-10       Impact factor: 5.952

2.  Fibro-Fatty Component is Important for the Long-Term Clinical Events in Patients Who Have Undergone Primary Percutaneous Coronary Intervention.

Authors:  Wan Ho Kim; Hyun Woong Park; Ki Hong Kim; In Girl Song; Dong Ju Yang; Chung Seop Lee; Young Hoon Seo; Taek Geun Kwon; Jang-Ho Bae
Journal:  Korean Circ J       Date:  2012-01-31       Impact factor: 3.243

3.  Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers.

Authors:  Hassan Shemirani; Faezeh Dehghani Tafti; Afshin Amirpour
Journal:  J Res Med Sci       Date:  2014-11       Impact factor: 1.852

4.  Association between tissue characteristics of coronary plaque and distal embolization after coronary intervention in acute coronary syndrome patients: insights from a meta-analysis of virtual histology-intravascular ultrasound studies.

Authors:  Song Ding; Longwei Xu; Fan Yang; Lingcong Kong; Yichao Zhao; Lingchen Gao; Wei Wang; Rende Xu; Heng Ge; Meng Jiang; Jun Pu; Ben He
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

5.  Predictors of delayed and no-reflow as recognized with Thrombolysis in Myocardial Infarction [TIMI] flow grade following Primary Percutaneous Coronary Angioplasty.

Authors:  M Bahrehmand; E Sadeghi; A Shafiee; Y Nozari
Journal:  J Med Life       Date:  2015

6.  Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: a virtual histology-intravascular ultrasound analysis.

Authors:  Young Joon Hong; Myung Ho Jeong; Yun Ha Choi; Jum Suk Ko; Min Goo Lee; Won Yu Kang; Shin Eun Lee; Soo Hyun Kim; Keun Ho Park; Doo Sun Sim; Nam Sik Yoon; Hyun Ju Youn; Kye Hun Kim; Hyung Wook Park; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  Eur Heart J       Date:  2009-02-19       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.